Related Experiment Videos
Hypertension in autosomal dominant polycystic kidney disease
1Division of Nephrology, Health Sciences Centre, Memorial University, St John's, Newfoundland, Canada.
Current Opinion in Nephrology and Hypertension
|September 1, 1995
Summary
Hypertension is common in autosomal dominant polycystic kidney disease, often driven by the renin-angiotensin system. While ACE inhibitors help manage blood pressure before kidney failure, their use in severe renal failure requires caution due to potential kidney function decline.
Area of Science:
- Nephrology
- Cardiology
- Genetics
Background:
- Autosomal dominant polycystic kidney disease (ADPKD) frequently presents with hypertension.
- The renin-angiotensin system (RAS) plays a key role in hypertension development in ADPKD, particularly before significant renal failure.
- Cardiovascular disease is a major concern in ADPKD patients.
Purpose of the Study:
- To review the role of hypertension in ADPKD.
- To discuss the implications of RAS activity on blood pressure management.
- To evaluate treatment strategies for hypertension in ADPKD, considering renal function.
Main Methods:
- Literature review of studies on hypertension in ADPKD.
- Analysis of the impact of RAS on blood pressure.
- Evaluation of antihypertensive treatments, including ACE inhibitors, in different stages of renal function.
Main Results:
- Increased RAS activity is a significant factor in ADPKD-related hypertension.
- Angiotensin-converting enzyme (ACE) inhibitors are effective for hypertension before renal failure.
- In severe renal failure, ACE inhibitors may worsen kidney function.
- Hypertension management is crucial for cardiovascular health but may not halt ADPKD progression.
Conclusions:
- Hypertension management is essential in ADPKD for cardiovascular protection.
- Careful consideration of renal function is necessary when using ACE inhibitors in ADPKD patients.
- Further research may be needed to optimize blood pressure control strategies in advanced ADPKD.